JZ Wang
YOU?
Author Swipe
View article: P.157 TERT expression predicts progression-free survival in meningiomas
P.157 TERT expression predicts progression-free survival in meningiomas Open
Background: TERT promoter mutation (TPM) is an established biomarker in meningiomas associated with aberrant TERT expression and reduced progression-free survival (PFS). TERT expression, however, has also been observed even in tumours with…
View article: F.2 Comprehensively mapping transcriptionally relevant histone modifications in aggressive meningioma leads to novel biologic insights and therapeutic vulnerabilities
F.2 Comprehensively mapping transcriptionally relevant histone modifications in aggressive meningioma leads to novel biologic insights and therapeutic vulnerabilities Open
Background: We recently identified four molecular subgroups of meningioma with distinct biology and outcomes. While two (MG3/MG4) are associated with poor outcome, they display divergent transcriptional profiles (enriched in metabolic and …
View article: GR.5 Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS malignancy
GR.5 Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS malignancy Open
Background: Liquid biopsy represents a major development in cancer research, with significant translational potential. Similarly, the integration of multiple molecular platforms has yielded novel insights into disease biology and heterogen…
View article: GR.6 Meningioma molecular classification predicts response to surgery and adjuvant radiotherapy: an integrated clinicomolecular analysis & prospective validation
GR.6 Meningioma molecular classification predicts response to surgery and adjuvant radiotherapy: an integrated clinicomolecular analysis & prospective validation Open
Background: Meningiomas are the most common intracranial tumor with surgery, dural margin treatment, and radiotherapy as cornerstones of therapy. Response to treatment continues to be highly heterogeneous even across tumors of the same gra…
View article: F.3 Multicentre prospective validation of integrated molecular classification of meningiomas and prediction of recurrence risk using DNA methylation
F.3 Multicentre prospective validation of integrated molecular classification of meningiomas and prediction of recurrence risk using DNA methylation Open
Background: Meningiomas have significant heterogeneity between patients, making prognostication challenging. For this study, we prospectively validate the prognostic capabilities of a DNA methylation-based predictor and multiomic molecular…
View article: P.104 Grade 3 meningioma survival, recurrence and functional outcomes in an international multicenter cohort
P.104 Grade 3 meningioma survival, recurrence and functional outcomes in an international multicenter cohort Open
Background: Meningiomas are the most common intracranial tumor, graded from 1 (benign) to 3 (malignant). The aim of this study was to identify clinical features associated with overall survival (OS), progression-free survival (PFS) and fun…
View article: F.3 Comprehensive multiplatform analysis of CDKN2A alterations in meningiomas
F.3 Comprehensive multiplatform analysis of CDKN2A alterations in meningiomas Open
Background: In meningiomas, CDKN2A/B deletions are associated with poor outcomes but are rare in most cohorts (1-5%). Large molecular datasets are therefore required to explore these deletions and their relationship to other prognostic CDK…
View article: P.049 Repeat surgery in recurrent glioblastoma: a systematic review and meta-analysis
P.049 Repeat surgery in recurrent glioblastoma: a systematic review and meta-analysis Open
Background: Recurrent glioblastoma portends a poor prognosis and the role of repeat surgery in improving survival remains uncertain. Our systematic review and meta-analysis aims to address whether re-resection provides a meaningful surviva…
View article: Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation
Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation Open